The standard of care for fit patients with Mantle Cell Lymphoma (MCL) includes cytarabine containing induction treatment and consolidation with BEAM (Carmustine, Etoposide, Cytarabine and Melphalan). Chemo-refractory cases have a poorer prognosis and are candidates for allogenic stem cell transplantation (allo-SCT). Targeted therapy, such as BTK-inhibitors or BCL-mimetics can be used to bridge patients to SCT. COVID-19, a novel coronavirus has the potential to cause life threatening immune dysregulation and cytokine release syndrome (CRS) resulting in respiratory failure. Haematology patients, particularly post allogenic stem cell transplant, are high risk for developing CRS due to T-lymphopenia. PD, a 55-year-old male, with chemo-refractory MCL tested positive for COVID-19 day + 45 post allo-SCT after presenting with mild gastrointestinal symptoms and remained positive for 70 days. At day + 92 relapse was confirmed by CT and axillary node biopsy. Ibrutinib, a BTK inhibitor, was commenced with resolution of symptoms and a negative test within 20 days. With minimal reduction in adenopathy, Ibrutinib was stopped at day +110, while Cytarabine and Venetoclax (BCL-mimetic) were commenced with Donor lymphocyte infusion at day +145 resulting in complete remission. Ibrutinib’s therapeutic role against COVID-19 is now being investigated in clinical trials.
| Published in | American Journal of Internal Medicine (Volume 9, Issue 1) |
| DOI | 10.11648/j.ajim.20210901.17 |
| Page(s) | 49-51 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2024. Published by Science Publishing Group |
Mantle Cell Lymphoma, Allogenic Stem-Cell Transplantation, COVID-19, Ibrutinib, BTK-inhibitor, Venetoclax, BCL2 Mimetic, Graft Versus Host Disease
| [1] | Delarue, R., Haioun, C., Ribrag, V., Brice, P., Delmer, A., & Tilly, H. et al. (2013). CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte. Blood, 121 (1), 48-53. doi: 10.1182/blood-2011-09-370320. |
| [2] | El-Sharkawi, D., & Iyengar, S. (2020). Haematological cancers and the risk of severe COVID-19: Exploration and critical evaluation of the evidence to date. British Journal Of Haematology, 190 (3), 336-345. doi: 10.1111/bjh.16956. |
| [3] | Eskelund, C., Kolstad, A., Jerkeman, M., Räty, R., Laurell, A., & Eloranta, S. et al. (2016). 15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau. British Journal Of Haematology, 175 (3), 410-418. doi: 10.1111/bjh.14241. |
| [4] | Eyre, T., Walter, H., Iyengar, S., Follows, G., Cross, M., & Fox, C. et al. (2018). Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy. Haematologica, 104 (2), e68-e71. doi: 10.3324/haematol.2018.198812. |
| [5] | Fogarty, H., Townsend, L., Ni Cheallaigh, C., Bergin, C., Martin-Loeches, I., & Browne, P. et al. (2020). COVID19 coagulopathy in Caucasian patients. British Journal Of Haematology, 189 (6), 1044-1049. doi: 10.1111/bjh.16749. |
| [6] | Hermine, O., Hoster, E., Walewski, J., Bosly, A., Stilgenbauer, S., & Thieblemont, C. et al. (2016). Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. The Lancet, 388 (10044), 565-575. doi: 10.1016/s0140-6736(16)00739-x. |
| [7] | Kakodkar, P., Kaka, N., & Baig, M. (2020). A Comprehensive Literature Review on the Clinical Presentation, and Management of the Pandemic Coronavirus Disease 2019 (COVID-19). Cureus. doi: 10.7759/cureus.7560. |
| [8] | Lin, A., Cuttica, M., Ison, M., & Gordon, L. (2020). Ibrutinib for chronic lymphocytic leukemia in the setting of respiratory failure from severe COVID-19 infection: Case report and literature review. Ejhaem, 1 (2), 596-600. doi: 10.1002/jha2.98. |
| [9] | Matías-Guiu, J., Montero-Escribano, P., Pytel, V., Porta-Etessam, J., & Matias-Guiu, J. (2020). Potential COVID-19 infection in patients with severe multiple sclerosis treated with alemtuzumab. Multiple Sclerosis And Related Disorders, 44, 102297. doi: 10.1016/j.msard.2020.102297. |
| [10] | McGee, M., August, A., & Huang, W. (2020). BTK/ITK dual inhibitors: Modulating immunopathology and lymphopenia for COVID-19 therapy. Journal Of Leukocyte Biology. doi: 10.1002/jlb.5covr0620-306r. |
| [11] | Ogimi, C., Greninger, A., Waghmare, A., Kuypers, J., Shean, R., & Xie, H. et al. (2017). Prolonged Shedding of Human Coronavirus in Hematopoietic Cell Transplant Recipients: Risk Factors and Viral Genome Evolution. The Journal Of Infectious Diseases, 216 (2), 203-209. doi: 10.1093/infdis/jix264. |
| [12] | Roué, G., & Sola, B. (2020). Management of Drug Resistance in Mantle Cell Lymphoma. Cancers, 12 (6), 1565. doi: 10.3390/cancers12061565. |
| [13] | Treon, S., Castillo, J., Skarbnik, A., Soumerai, J., Ghobrial, I., & Guerrera, M. et al. (2020). The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients. Blood, 135 (21), 1912-1915. doi: 10.1182/blood.2020006288. |
| [14] | Voelker, R. (2020). CAR-T Therapy Is Approved for Mantle Cell Lymphoma. JAMA, 324 (9), 832. doi: 10.1001/jama.2020.15456. |
| [15] | Woyach, J. (2020). Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization - Full Text View – ClinicalTrials.gov. Retrieved 29 November 2020, from https://clinicaltrials.gov/ct2/show/NCT04439006. |
APA Style
James Dillon, Elizabeth Higgins, Carmel-Ann Galligan, Majella Moran, Brendan Crowley, et al. (2021). Relapsed Mantle Cell Lymphoma, Allogenic Stem Cell Transplantation and COVID-19. American Journal of Internal Medicine, 9(1), 49-51. https://doi.org/10.11648/j.ajim.20210901.17
ACS Style
James Dillon; Elizabeth Higgins; Carmel-Ann Galligan; Majella Moran; Brendan Crowley, et al. Relapsed Mantle Cell Lymphoma, Allogenic Stem Cell Transplantation and COVID-19. Am. J. Intern. Med. 2021, 9(1), 49-51. doi: 10.11648/j.ajim.20210901.17
AMA Style
James Dillon, Elizabeth Higgins, Carmel-Ann Galligan, Majella Moran, Brendan Crowley, et al. Relapsed Mantle Cell Lymphoma, Allogenic Stem Cell Transplantation and COVID-19. Am J Intern Med. 2021;9(1):49-51. doi: 10.11648/j.ajim.20210901.17
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.ajim.20210901.17,
author = {James Dillon and Elizabeth Higgins and Carmel-Ann Galligan and Majella Moran and Brendan Crowley and Ciaran Bannan and Carmel Waldron and Christopher Larry Bacon and Elisabeth Vandenberghe},
title = {Relapsed Mantle Cell Lymphoma, Allogenic Stem Cell Transplantation and COVID-19},
journal = {American Journal of Internal Medicine},
volume = {9},
number = {1},
pages = {49-51},
doi = {10.11648/j.ajim.20210901.17},
url = {https://doi.org/10.11648/j.ajim.20210901.17},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajim.20210901.17},
abstract = {The standard of care for fit patients with Mantle Cell Lymphoma (MCL) includes cytarabine containing induction treatment and consolidation with BEAM (Carmustine, Etoposide, Cytarabine and Melphalan). Chemo-refractory cases have a poorer prognosis and are candidates for allogenic stem cell transplantation (allo-SCT). Targeted therapy, such as BTK-inhibitors or BCL-mimetics can be used to bridge patients to SCT. COVID-19, a novel coronavirus has the potential to cause life threatening immune dysregulation and cytokine release syndrome (CRS) resulting in respiratory failure. Haematology patients, particularly post allogenic stem cell transplant, are high risk for developing CRS due to T-lymphopenia. PD, a 55-year-old male, with chemo-refractory MCL tested positive for COVID-19 day + 45 post allo-SCT after presenting with mild gastrointestinal symptoms and remained positive for 70 days. At day + 92 relapse was confirmed by CT and axillary node biopsy. Ibrutinib, a BTK inhibitor, was commenced with resolution of symptoms and a negative test within 20 days. With minimal reduction in adenopathy, Ibrutinib was stopped at day +110, while Cytarabine and Venetoclax (BCL-mimetic) were commenced with Donor lymphocyte infusion at day +145 resulting in complete remission. Ibrutinib’s therapeutic role against COVID-19 is now being investigated in clinical trials.},
year = {2021}
}
TY - JOUR T1 - Relapsed Mantle Cell Lymphoma, Allogenic Stem Cell Transplantation and COVID-19 AU - James Dillon AU - Elizabeth Higgins AU - Carmel-Ann Galligan AU - Majella Moran AU - Brendan Crowley AU - Ciaran Bannan AU - Carmel Waldron AU - Christopher Larry Bacon AU - Elisabeth Vandenberghe Y1 - 2021/01/30 PY - 2021 N1 - https://doi.org/10.11648/j.ajim.20210901.17 DO - 10.11648/j.ajim.20210901.17 T2 - American Journal of Internal Medicine JF - American Journal of Internal Medicine JO - American Journal of Internal Medicine SP - 49 EP - 51 PB - Science Publishing Group SN - 2330-4324 UR - https://doi.org/10.11648/j.ajim.20210901.17 AB - The standard of care for fit patients with Mantle Cell Lymphoma (MCL) includes cytarabine containing induction treatment and consolidation with BEAM (Carmustine, Etoposide, Cytarabine and Melphalan). Chemo-refractory cases have a poorer prognosis and are candidates for allogenic stem cell transplantation (allo-SCT). Targeted therapy, such as BTK-inhibitors or BCL-mimetics can be used to bridge patients to SCT. COVID-19, a novel coronavirus has the potential to cause life threatening immune dysregulation and cytokine release syndrome (CRS) resulting in respiratory failure. Haematology patients, particularly post allogenic stem cell transplant, are high risk for developing CRS due to T-lymphopenia. PD, a 55-year-old male, with chemo-refractory MCL tested positive for COVID-19 day + 45 post allo-SCT after presenting with mild gastrointestinal symptoms and remained positive for 70 days. At day + 92 relapse was confirmed by CT and axillary node biopsy. Ibrutinib, a BTK inhibitor, was commenced with resolution of symptoms and a negative test within 20 days. With minimal reduction in adenopathy, Ibrutinib was stopped at day +110, while Cytarabine and Venetoclax (BCL-mimetic) were commenced with Donor lymphocyte infusion at day +145 resulting in complete remission. Ibrutinib’s therapeutic role against COVID-19 is now being investigated in clinical trials. VL - 9 IS - 1 ER -
Information
Email: